SCHEMBL6586534

SCHEMBL6586534

c1ccc(COc2ccc3cccc(N(Cc4ccccc4)Cc4ccccc4)c3c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.58
CYP3A4 P08684 1/20 0.49
BCHE P06276 3/20 0.48
PLAU P00749 1/20 0.46
PLAT P00750 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
MAOB P27338 7/20 0.44
ACHE P22303 3/20 0.44
MAOA P21397 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
MTNR1A P48039 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL250804 0.84 NR3C1 (0.48) MEN1MTNR1AKMT2A
SCHEMBL10606515 0.78 ALOX5 (0.67) ALOX5CYP3A4BCHEPLAUPLAT
SCHEMBL6541752 0.77 L3MBTL1 (0.45) KMT2A
SCHEMBL38662923 0.77 ALOX5 (0.65) ALOX5CYP3A4PLAUPLATMRGPRX4
SCHEMBL22703560 0.77 ALOX5 (0.65) ALOX5CYP3A4BCHEPLAUPLAT
SCHEMBL4079350 0.77 ALOX5 (0.65) ALOX5CYP3A4BCHEPLAUPLAT
SCHEMBL4477944 0.77 ALOX5 (0.65) ALOX5CYP3A4BCHEPLAUPLAT
SCHEMBL2747987 0.76 SMN1; SMN2 (0.50) ALOX5MAOBMEN1NPC1KMT2A
SCHEMBL2747168 0.76 MAOB (0.46) ALOX5BCHEMAOBACHEMAOA
SCHEMBL51460 0.75 ALOX5 (1.00) ALOX5CYP3A4MRGPRX4MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259875-A1 Amine derivatives BAYER HEALTHCARE AG (DE) 2004-12-23 US disclosed
EP-1414788-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS Bayer HealthCare AG (DE) 2004-05-06 EP disclosed
WO-2003014064-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259875-A1 Amine derivatives AVPR1A, GRIN1, OPRL1 ALOX5 658/4885CYP3A4 4160/4885BCHE 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.